 By Steven Ralston, CFA CSE:HUGE.CN NASDAQ:HUGE READ THE FULL HUGE.CN RESEARCH REPORT FSD Pharma CSE:HUGE.CN NASDAQ:HUGE continues to evolve into a specialty, biotech pharmaceutical RD; company as management advances its strategic objective of developing, over time, a pipeline of FDA-approved synthetic compounds that target the human endocannabinoid system. Through the acquisition of 